Literature DB >> 11035377

Complete remission of idiopathic myelofibrosis following donor lymphocyte infusion after failure of allogeneic transplantation: demonstration of a graft-versus-myelofibrosis effect.

F Cervantes1, M Rovira, A Urbano-Ispizua, M Rozman, E Carreras, E Montserrat.   

Abstract

A patient with idiopathic myelofibrosis (IM) in the osteosclerotic phase received an allogeneic stem cell transplant. Hemopoietic engraftment was rapid, and full donor chimerism was observed on day +70. However, a few months later, replacement of donor hemopoiesis by the patient's 20q- cell clone was observed, followed by reappearance of the blood IM features, marrow fibrosis and osteosclerosis. At 8 months from transplant donor lymphocytes were infused, which induced chronic GVHD. This resulted in normalization of the blood, with disappearance of the fibrosis and osteosclerosis, effects which persisted 20 months later. This case provides evidence for a graft-versus-disease effect in IM.

Entities:  

Mesh:

Year:  2000        PMID: 11035377     DOI: 10.1038/sj.bmt.1702568

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  10 in total

Review 1.  Indications and outcomes of reduced-toxicity hematopoietic stem cell transplantation in adult patients with hematological malignancies.

Authors:  S Fadilah Abdul Wahid
Journal:  Int J Hematol       Date:  2013-04-13       Impact factor: 2.490

Review 2.  Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors.

Authors:  Vikas Gupta; Parameswaran Hari; Ronald Hoffman
Journal:  Blood       Date:  2012-06-14       Impact factor: 22.113

Review 3.  Allogeneic hematopoietic cell transplantation in myelofibrosis with myeloid metaplasia.

Authors:  William J Hogan; Mark R Litzow; Ayalew Tefferi
Journal:  Curr Hematol Malig Rep       Date:  2007-02       Impact factor: 3.952

Review 4.  Reduced-intensity conditioning followed by allogeneic hematopoietic stem cell transplantation in myelofibrosis.

Authors:  Haefaa Alchalby; Nicolaus Kröger
Journal:  Curr Hematol Malig Rep       Date:  2010-04       Impact factor: 3.952

Review 5.  Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party.

Authors:  Donal P McLornan; Juan Carlos Hernandez Boluda; Tomasz Czerw; Nicholas Cross; H Joachim Deeg; Marcus Ditschkowski; Mufaddal T Moonim; Nicola Polverelli; Marie Robin; Mahmoud Aljurf; Eibhlin Conneally; Patrick Hayden; Ibrahim Yakoub-Agha
Journal:  Leukemia       Date:  2021-05-26       Impact factor: 11.528

Review 6.  Current Challenges in Stem Cell Transplantation in Myelofibrosis.

Authors:  Nicolaus Kröger
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

7.  MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis.

Authors:  Damiano Rondelli; Judith D Goldberg; Luis Isola; Leah S Price; Tsiporah B Shore; Michael Boyer; Andrea Bacigalupo; Alessandro Rambaldi; Marco Scarano; Rebecca B Klisovic; Vikas Gupta; Bjorn Andreasson; John Mascarenhas; Meir Wetzler; Alessandro M Vannucchi; Josef T Prchal; Vesna Najfeld; Attilio Orazi; Rona S Weinberg; Crystal Miller; Giovanni Barosi; Lewis R Silverman; Giuseppe Prosperini; Roberto Marchioli; Ronald Hoffman
Journal:  Blood       Date:  2014-06-24       Impact factor: 22.113

Review 8.  Allogeneic hematopoietic cell transplantation for patients with myelofibrosis.

Authors:  Dae Young Zang; H Joachim Deeg
Journal:  Curr Opin Hematol       Date:  2009-03       Impact factor: 3.284

Review 9.  Immunotherapy in Myeloproliferative Diseases.

Authors:  Lukas M Braun; Robert Zeiser
Journal:  Cells       Date:  2020-06-26       Impact factor: 6.600

Review 10.  Inflammation as a Keystone of Bone Marrow Stroma Alterations in Primary Myelofibrosis.

Authors:  Christophe Desterke; Christophe Martinaud; Nadira Ruzehaji; Marie-Caroline Le Bousse-Kerdilès
Journal:  Mediators Inflamm       Date:  2015-11-12       Impact factor: 4.711

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.